The compound library

25 compounds, one format.

Every summary answers the same four questions: how the compound works, what it is most studied for, what the notable studies found and at what doses, and how strong that evidence really is. Animal or human, said plainly.

Recovery & repair 2

ANIMAL / IN VITRO9 refs BPC-157 Synthetic gastric pentadecapeptide A synthetic gastric peptide studied mostly in rat models of tendon, gut and blood vessel repair, with only small uncontrolled human reports. Read the research ANIMAL / IN VITRO8 refs TB-500 Synthetic thymosin beta-4 fragment Sold as a synthetic fragment of thymosin beta-4; most research, including small human eye-drop trials, studied the full-length protein instead. Read the research

Metabolic 9

FDA APPROVED5 refs Orforglipron Oral non-peptide GLP-1 receptor agonist An oral, non-peptide small-molecule GLP-1 receptor agonist, FDA-approved in 2026 for chronic weight management after a 72-week phase 3 trial in 3,127 adults. Read the research FDA APPROVED7 refs Semaglutide Acylated GLP-1 receptor agonist peptide A once-weekly GLP-1 receptor agonist and one of the most extensively trialed peptides in metabolic research, including a 17,604-person cardiovascular outcomes trial. Read the research FDA APPROVED6 refs Tirzepatide Dual GIP/GLP-1 receptor agonist peptide A dual GIP and GLP-1 receptor agonist that produced greater weight reduction than semaglutide in a 72-week head-to-head randomized trial. Read the research HUMAN RCT4 refs Bimagrumab Monoclonal antibody, not a peptide Not a peptide but an antibody against activin type II receptors, tested in randomized trials on body composition in obesity and sarcopenia. Read the research HUMAN RCT3 refs Cagrilintide Long-acting acylated amylin analogue A long-acting amylin analogue studied mainly as a weekly partner to semaglutide, with a 3,417-person phase 3 trial of the combination. Read the research HUMAN RCT5 refs Retatrutide Triple GIP/GLP-1/glucagon receptor agonist An investigational triple GIP, GLP-1 and glucagon receptor agonist whose phase 3 trials reported mean weight reductions of 25% or more at the highest dose. Read the research MIXED EVIDENCE6 refs AOD-9604 Modified growth hormone fragment peptide A modified growth hormone fragment developed as an obesity drug, with rodent fat-loss data, a pooled human safety analysis and unpublished, conflicting efficacy trials. Read the research ANIMAL / IN VITRO4 refs 5-Amino-1MQ Small-molecule NNMT inhibitor, not a peptide A small-molecule NNMT enzyme inhibitor, not a peptide, studied only in mice and cultured cells for fat mass, glucose handling and aged muscle repair. Read the research ANIMAL / IN VITRO4 refs MOTS-c Mitochondrial-derived signaling peptide A 16-amino-acid peptide encoded in mitochondrial DNA, studied in mice for insulin sensitivity and in humans only as a measured blood marker. Read the research

Longevity 3

FDA APPROVED9 refs SS-31 Mitochondria-targeted aromatic-cationic tetrapeptide A mitochondria-targeted tetrapeptide with an FDA accelerated approval in Barth syndrome and large negative trials in mitochondrial myopathy. Read the research MIXED EVIDENCE9 refs Glutathione Endogenous antioxidant tripeptide An antioxidant tripeptide the body makes itself, studied by oral, liposomal, intravenous, inhaled, intranasal and topical routes, with conflicting results. Read the research MINIMAL EVIDENCE7 refs Epitalon Synthetic pineal tetrapeptide A four-amino-acid pineal peptide studied mostly in cell culture and rodents, with the human data belonging to an older bovine pineal extract. Read the research

Cognition & mood 2

EARLY HUMAN8 refs Selank Synthetic tuftsin analog heptapeptide A tuftsin-derived heptapeptide registered in Russia for anxiety, studied in small Russian clinical studies and in rat models of anxiety and withdrawal. Read the research EARLY HUMAN5 refs Semax Synthetic ACTH(4-10) analog heptapeptide An ACTH-derived heptapeptide registered as a medicine in Russia, studied mostly in rodent brain-injury models and small Russian clinical studies. Read the research

Immune 2

MIXED EVIDENCE8 refs Thymosin alpha-1 Synthetic thymic immunomodulatory peptide A 28-amino-acid thymic peptide approved abroad as Zadaxin and tested in randomized trials in hepatitis B, sepsis and melanoma, with mixed results. Read the research ANIMAL / IN VITRO6 refs KPV Alpha-MSH C-terminal tripeptide The three-amino-acid tail of alpha-MSH, studied almost entirely in mouse colitis models and cultured gut and immune cells. Read the research

Skin 2

MIXED EVIDENCE7 refs GHK-Cu Copper-binding tripeptide complex A copper-binding tripeptide studied mostly in fibroblast cultures and wound models, with a few small skin trials and one large negative ulcer trial. Read the research MINIMAL EVIDENCE7 refs Melanotan II Synthetic cyclic α-MSH analogue A synthetic α-MSH analogue tested in small 1990s studies for tanning and erections, never approved, and linked in case reports to mole changes. Read the research

Growth hormone axis 3

FDA APPROVED6 refs Tesamorelin Synthetic GHRH(1-44) analog An FDA-approved GHRH analog, tested in phase 3 trials on visceral fat in HIV and in smaller trials on liver fat and cognition. Read the research EARLY HUMAN5 refs CJC-1295 Long-acting synthetic GHRH analog A long-acting GHRH analog whose albumin-binding (DAC) form raised GH and IGF-1 for days in small phase 1 studies in healthy adults. Read the research EARLY HUMAN7 refs Ipamorelin Selective pentapeptide GH secretagogue A selective ghrelin-receptor agonist that released GH without raising ACTH or cortisol in swine, later tested in a phase 2 postoperative ileus trial. Read the research

Sexual health 1

FDA APPROVED6 refs PT-141 Synthetic melanocortin receptor agonist peptide A melanocortin receptor agonist peptide, FDA-approved in 2019 for low sexual desire in premenopausal women after two 24-week phase 3 trials. Read the research

Sleep 1

MIXED EVIDENCE6 refs DSIP Nonapeptide sleep-research neuropeptide A nonapeptide isolated from rabbits in 1977, tested in small 1980s and 1990s human sleep studies with weak and inconsistent results. Read the research

How the evidence tiers work

  • FDA APPROVEDApproved by FDA for at least one indication.
  • HUMAN RCTRandomized controlled trial in humans, n>100, published.
  • EARLY HUMANHuman trial, small or uncontrolled, or phase 1/2 only.
  • MIXED EVIDENCEHuman data exists and conflicts, or endpoints are surrogate.
  • ANIMAL / IN VITRONo published human efficacy trials. Rodent or cell data only.
  • MINIMAL EVIDENCELittle or no peer-reviewed data of any kind; largely anecdote.